ArticleNuclear medicine and molecular imaging2019
Predictive Value of Interim and End-of-Therapy 18F-FDG PET/CT in Patients with Follicular Lymphoma.
Article in Nuclear medicine and molecular imaging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 22 citations in OpenAlex.
- Prognostic role of interim PET in follicular lymphoma: a post hoc study of FOLL12 trial by Fondazione Italiana Linfomi.Blood advances · 2025Trial
- Exploratory Study to Evaluate the Impact of Interim PET/CT Assessment in First-Line Follicular Lymphoma.Cancers · 2025Article
- Baseline [BMC cancer · 2025Article
- Review
- Evaluation of Semiautomatic and Deep Learning-Based Fully Automatic Segmentation Methods on [Journal of digital imaging · 2023Article
- Prognostic value of interimAnnals of hematology · 2023Article
- FDG PET/CT Maximum Tumor Dissemination to Predict Recurrence in Patients with Diffuse Large B-Cell Lymphoma.Nuclear medicine and molecular imaging · 2023Article
- Interim Positron Emission Tomography During Frontline Chemoimmunotherapy for Follicular Lymphoma.HemaSphere · 2023Article
- Duodenal-type follicular lymphoma inAmerican journal of nuclear medicine and molecular imaging · 2023Article
- Article
- Limited benefit of additional contrast-enhanced CT to end-of-treatment PET/CT evaluation in patients with follicular lymphoma.Scientific reports · 2021Article
- Significance of initial, interim and end-of-therapyCancer cell international · 2021Article
- Radiotherapy in Follicular Lymphoma Staged byBiomedicines · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose
methodsFL staging and response assessment PET/CT images from 2013 to 2015 were retrospectively reviewed. PET
resultsThirty-three patients with set of baseline, interim, and end-of-induction therapy PET/CT studies were included. Ten patients (30.3%) had progression. The median progression-free survival (PFS) was 38.8 months (range 3.5-72.7 months). On PET
conclusionFor patients with FL, PET
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.